NNMT Biology and Metabolic Role
What NNMT Does
NNMT catalyzes the transfer of a methyl group from SAM to nicotinamide, consuming both the methyl group and the nicotinamide simultaneously:SAM + Nicotinamide → SAH + 1-Methylnicotinamide
This reaction has two metabolically significant consequences: 1. Nicotinamide depletion: Nicotinamide is a NAD+ precursor. NNMT activity removes nicotinamide from the NAD+ synthesis pathway, reducing NAD+ availability. 2. SAM consumption: SAM is the universal methyl donor for >200 methylation reactions including DNA methylation, histone methylation, and neurotransmitter synthesis. NNMT acts as a metabolic "methyl sink," draining SAM without productive purpose.
NNMT in Adipose Tissue
NNMT is highly expressed in white adipose tissue (WAT). In obesity, adipose NNMT is significantly upregulated, creating a vicious cycle: high NNMT activity depletes NAD+ and SAM, impairing mitochondrial function, reducing fatty acid oxidation, and reducing the methylation capacity needed for proper gene expression. Preclinical models of NNMT knockdown show protection against diet-induced obesity and insulin resistance.5-Amino-1MQ as an NNMT Inhibitor
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small molecule that competitively inhibits NNMT by occupying its nicotinamide binding site. It is not a peptide but is often grouped with metabolic research compounds in the peptide community.
Mechanism
By blocking NNMT, 5-Amino-1MQ: - Preserves nicotinamide → increases NAD+ synthesis flux - Preserves SAM → restores cellular methylation capacity - Reduces 1-MNA production, which itself has complex biological effectsPreclinical Evidence
Mouse models have shown that 5-Amino-1MQ treatment leads to: - Reduced adipose mass without caloric restriction - Improved insulin sensitivity - Increased energy expenditure - Upregulation of genes involved in mitochondrial biogenesisNo human clinical trials on 5-Amino-1MQ have been completed as of 2025. All effects are from rodent preclinical data.
Calculate your NNMT Inhibition dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Stacking with Metabolic Peptides
NNMT inhibition has logical complementarity with several metabolic peptides:
MOTS-c
MOTS-c activates AMPK and drives flux through one-carbon metabolism. Since NNMT inhibition preserves both SAM (used in methylation) and nicotinamide (used in NAD+ synthesis), combining 5-Amino-1MQ with MOTS-c theoretically removes two metabolic constraints that might otherwise limit MOTS-c's downstream effects. This is the most discussed stack in the community.GLP-1 Analogs (Semaglutide, Tirzepatide)
GLP-1 receptor agonists work via incretin-mediated insulin secretion and satiety signaling. NNMT inhibition addresses a different axis, adipose metabolic dysfunction. The combination targets both appetite regulation (GLP-1) and adipose remodeling (NNMT inhibition). Some researchers hypothesize NNMT inhibition may address fat loss that plateaus on GLP-1 therapy.NAD+ Precursors (NR, NMN)
NR and NMN raise NAD+ by providing substrate. NNMT inhibition conserves nicotinamide, complementing precursor supplementation. In theory: precursors increase the NAD+ input and NNMT inhibition reduces the drain. In practice, this combination has not been studied.Safety and Research Status
5-Amino-1MQ has no published human safety data as of 2025. All dosing used in the research community is extrapolated from rodent studies with dose conversion adjustments.
Theoretical concerns: - 1-MNA (the product NNMT makes) has protective cardiovascular and neurological roles in some contexts, systemic NNMT inhibition may reduce 1-MNA in tissues where it is beneficial - SAM excess from reduced NNMT activity could theoretically affect methylation balance, particularly in high-dose or prolonged use
Research use only. Not approved for human use. Consult a physician before use.
References
- [1]Ryu D, et al. "A SIRT7-Dependent Acetylation Switch of GABPbeta1 Controls Mitochondrial Function." Cell Metabolism. 2014.
- [2]Kannt A, et al. "Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with characteristics of the metabolic syndrome." Diabetologia. 2015.
- [3]Hong S, et al. "Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization." Nature Medicine. 2015.
- [4]Neelakantan H, et al. "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochemical Pharmacology. 2018.